Is Ascentage Pharma Group International (ASPHF) a Buy, Sell, or Hold?
OTC : ASPHF
Ascentage Pharma Group International
$4.53 USD
$0 (0.0%)
- Volume
- 1K
- Average Volume
- 5
- Market Capitalization
- $1.69B
- P/E Ratio
- -9.83
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $10.65
- Year Low
- $4.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.79
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Dajun Yang |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ASPHF |
| CUSIP | G0519B102 |
| CIK | 0002023311 |
| Web | https://www.ascentage.cn |
| Phone | 86 512 8555 7777 |
| Currency | USD |
| Employees | 767 |
| Country | CN |
Liquidity
| Debt-to-Equity Ratio | 1.49 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.79 |
| Quick Ratio | 1.77 |
| Cash Ratio | 1.50 |
Sales & Book Value
| Annual Sales | $559.3M |
| Price / Sales | 22.26 |
| Cash Flow | -3.35 |
| Price / Cash Flow | -10.19 |
| Price / Book | 9.51 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$3.43 |
| Trailing P/E Ratio | -9.83 |
| PEG Ratio | 0.05 |
| P/E Growth | 0.05 |
| Net Income | -$1.21B |
| Net Margin | -216.71% |
| Pretax Margin | -215.54% |
| Return on Equity | -123.74% |
| Return on Assets | -31.07% |
Financials Score
| AltmanZ Score | -0.01 |
| Piotroski Score | 4.00 |
| Working Capital | 1.3B |
| Total Assets | 3.97B |
| Ebit | -1.05B |
| Market Cap | 11.44B |
| Total Liabilities | 2.63B |
Poll Results
About Ascentage Pharma Group International (OTC:ASPHF) Stock
Ascentage Pharma Group International (ASPHF) is a clinical-stage biotechnology firm that develops novel therapeutic agents. Its primary focus areas include oncological conditions, chronic hepatitis B (HBV), and age-related diseases, with operations concentrated in the United States and Mainland China. A cornerstone of its pipeline is HQP1351, a BCR-ABL inhibitor specifically engineered to combat BCR-ABL mutants, including those bearing the challenging T315I mutation. This compound is particularly aimed at individuals suffering from chronic phase chronic myeloid leukemia (CML) that has proven resistant to conventional tyrosine kinase inhibitor (TKI) treatments. Ascentage's diverse pipeline further includes APG-2575, an orally administered selective Bcl-2 inhibitor currently in Phase Ib/II c ... linical studies for hematologic malignancies and solid tumors. Another asset is APG-115, an oral small molecule designed to disrupt the MDM2-p53 protein-protein interaction, also intended for solid tumors and blood cancers. Additionally, APG-1387, a small molecule inhibitor of apoptosis proteins, is being developed for advanced solid tumors and chronic HBV infection. Beyond these, Ascentage is actively advancing APG-1252, a small molecule drug engineered to induce apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins, targeting small cell lung cancer (SCLC), lymphoma, and various other solid tumors. Other ongoing projects include APG-2449 for non-small-cell lung carcinoma, and APG-5918, a promising orally available and selective EED inhibitor with best-in-class potential, currently in the preclinical stage. Furthermore, APG-265 is in IND-enabling studies for hematological and solid malignancies, while UBX1967/1325, aimed at the Bcl family for diabetic macular edema (DME), is undergoing Phase II development. The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical enterprises, as well as respected academic institutions. Notable partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Founded in 2009, Ascentage Pharma's corporate headquarters are situated in Suzhou, China.
Frequently Asked Questions
-
What is the current Ascentage Pharma Group International (ASPHF) stock price?
-
Ascentage Pharma Group International(OTC:ASPHF) stock price is $4.53 in the last trading session. During the trading session, ASPHF stock reached the peak price of $10.65 while $4.53 was the lowest point it dropped to. The percentage change in ASPHF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ASPHF stock was $0.
-
ASPHF's industry and sector of operation?
-
The OTC listed ASPHF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ASPHF?
-
Dajun Yang | Co-Founder, Chairman & Chief Executive Officer
Chongdong Fu | Senior Vice President & Head of CMC
Manish Tandon | SVP of Business Development
Zhichao Si | Head of Commercial
Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director -
How many employees does ASPHF have?
-
Number of ASPHF employees currently stands at 767. ASPHF operates from Suzhou Industrial Park, Suzhou, JS 215000, CN.
-
Link for ASPHF official website?
-
Official Website of ASPHF is: https://www.ascentage.cn
-
How do I contact ASPHF?
-
ASPHF could be contacted at phone #86 512 8555 7777 and can also be accessed through its website. ASPHF operates from Suzhou Industrial Park, Suzhou, JS 215000, CN.
-
How many shares of ASPHF are traded daily?
-
The average number of ASPHF shares traded daily for last 3 months was 5.
-
What is the market cap of ASPHF currently?
-
The market value of ASPHF currently stands at $1.69B with its latest stock price at $4.53